← Human Trials & Peer-Reviewed Studies
Time course responses of serum GH, insulin, IGF-1, IGFBP1, and IGFBP3 concentrations after heavy resistance exercise in trained and untrained men
Plain-language guide to PMID 21983797 (2012): randomized controlled trial study of IGF-1 LR3 in 19 men, insulin resistance, prediabetes & type 2 diabetes.
Key Facts
- PMID
- 21983797
- Journal
- Endocrine
- Year
- 2012
- Study type
- Randomized Controlled Trial
- Authors
- Hasani-Ranjbar S et al. (5 authors)
- DOI
- 10.1007/s12020-011-9537-3
What This Study Did, in Plain Language
What Was Tested
Researchers studied IGF-1 LR3 in the context of insulin resistance, prediabetes & type 2 diabetes in this randomized controlled trial publication.
To investigate the effect of heavy resistance exercise on IGF-1 system, 19 healthy trained men and 15 healthy untrained men volunteered to participate in this study.
Why It Was Studied
The subjects were randomly divided into experimental and control groups.
The blood samples were taken from all subjects four times; before (T1), immediately after (T2), 5 (T3), and 8 (T4) hours after exercise.
Who Took Part
The abstract describes 19 men taking part.
By PubMed's age tags, the people studied were adults, men only.
How the Study Was Run
In design terms this was a randomized study.
The men were allocated by chance, so the IGF-1 LR3 group and the comparison group should start out alike.
What Was Measured
PubMed files the paper under topics including Body Mass Index, Growth Hormone, Insulin, Insulin-Like Growth Factor Binding Protein 1, Insulin-Like Growth Factor Binding Protein 3, Insulin-Like Growth Factor I and Life Style.
What This Means in Plain Language
The paper is a randomized study of IGF-1 LR3 in 19 men in people with insulin resistance, prediabetes & type 2 diabetes.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2012 (Endocrine), a journal based in United States.
More context: the IGF-1 LR3 compound page, Insulin resistance, prediabetes & type 2 diabetes research.
Our Notes on the Compound
IGF-1 LR3: A modified IGF-1 analog that escapes binding proteins, so it stays active ≥24 h.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.